Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 11—November 2022
Research

Effectiveness of Second mRNA COVID-19 Booster Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents

Yoo-Yeon Kim1, Young June Choe1, Jia Kim, Ryu Kyung Kim, Eun Jung Jang, Seon Kyeong Park, Do-Sang Lim, Seonju Yi, Sangwon Lee, Geun-Yong Kwon, Jee Yeon Shin, Sang-Yoon Choi, Mi Jin Jeong, and Young-Joon ParkComments to Author 
Author affiliations: Korea Disease Control and Prevention Agency, Cheongju, South Korea (Y.-Y. Kim, J. Kim, R.K. Kim, E.J. Jang, S.K. Park, D.-S. Lim, S. Yi, S. Lee, G.-Y. Kwon, J.Y. Shin, S.-Y. Choi, M.J. Jeong, Y.-J. Park); Korea University Anam Hospital, Seoul, South Korea (Y.J. Choe)

Main Article

Table 3

Incidence of SARS-CoV-2 infection, critical infection, and death among immunocompromised persons and LTCF residents after first and second mRNA booster vaccine, South Korea, February–May 2022

Category
 Follow-up time, d
0
 10.6
 21.2
 31.8
 42.4
 53.0
All infections
First booster
No. at risk 972,449 937,931 822,346 653,579 540,367 470,791
No. events 0 24,129 76,592 158,059 227,409 268,278
Second booster
No. at risk 850 10,365 72,142 150,436 175,606 192,093
No. events
 0
 24
 1,369
 10,375
 29,070
 45,110
Critical infections
First booster
No. at risk 972,449 937,931 822,346 653,579 540,367 470,791
No. events 0 377 998 1,762 2,298 2,609
Second booster
No. at risk 850 10,365 72,142 150,436 175,606 192,093
No. events
 0
 0
 8
 68
 218
 342
Deaths
First booster
No. at risk 972,449 937,931 822,346 653,579 540,367 470,791
No. events 0 283 782 1,445 1,901 2,148
Second booster
No. at risk 850 10,365 72,142 150,436 175,606 192,093
No. events 0 0 5 58 193 293

Main Article

1These authors contributed equally to this article.

Page created: September 16, 2022
Page updated: October 21, 2022
Page reviewed: October 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external